Rapid Clinical Updates: Heart Failure - Session 3 Evaluation

September 30, 2021

This activity was made possible in part by an educational grant from Novartis.

The SHM Clinical Rapid Updates in Heart Failure series continues with this session covering quality improvement focused approach for heart failure patient during hospitalization.

Specific subtopics addressed in this session include:

1.    Describe novel HF therapies that are potential QI targets including SGLT2 inhibitors alone and in combination w/ ANRI
2.    Describe results of recent studies as potential QI targets including EMPRROR Reducediv and DAPA HFv 
3.    Discuss QI efforts in this area

This session is moderated by Dr. Joseph Sweigart, MD, SFHM. Our panelists include Dr. Lily Ackerman, MD, ScM, Dr. Gurpreet Sodhi, MD, and Dr. Ebrahim Barkoudah, MD, FACP, MPH, SFHM

Additional Information

PDF icon SHM HF 3 Handout.pdf255.69 KB
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-physician
Course opens: 
Course expires: 
Event starts: 
09/30/2021 - 4:00pm EDT
Event ends: 
09/30/2021 - 5:00pm EDT
Your cost:
Faculty and Disclosures

Planners and faculty for this activity have no relevant relationships to disclose unless noted below.

Dr. Ebrahim Barkoudah discloses the following relevant financial or advisory relationships:

  • Advisory fees from Portola, Janssen, Novartis, and Pfizer/Bristol-Myers-Squibb to Hospital Medicine and Cardiovascular Medicine research
  • Research support payments from National Institutes of Health/National Heart, Lung, and Blood Institute; Bristol Myers Squibb; Janssen. Payments made to Brigham and Women's Hospital for performing clinical endpoints sponsored by various entities
SHM Conflict of Interest Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, SHM requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. SHM resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. All relevant financial relationships shall be disclosed to participants prior to the start of the activity.

Furthermore, SHM seeks to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SHM is committed to providing its learners with high-quality CME activities that promote improvements in healthcare and not those of a commercial interest.

Accreditation Statement

The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Statement Designation

The Society of Hospital Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in this activity

SHM is dedicated to promoting the highest quality care for all hospitalized patients. SHM is committed to promoting excellence in the practice of hospital medicine through education, advocacy and research.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-physician


Your cost:
Please login or register to take this course.

Click the START button to enter the webinar post-test and evaluation, and claim CME.

Or click the OVERVIEW tab above to download the SLIDE DECK and HANDOUT from this session.